The treatment of patients with refractory/relapsed B-Cell non-Hodgkin lymphoma (NHL) is evolving due to the availability of novel drugs. Allogeneic stem cell transplantation (alloSCT) can be curative, but its morbidity and mortality remain a matter of concern. We conducted a multicentre prospective phase II trial to evaluate the benefit of including only one dose of Rituximab (R) in the conditioning regimen before alloSCT. The primary end-point was progression-free survival. The study enrolled 121 patients with relapsed/refractory B-cell lymphomas. The conditioning regimen consisted of thiotepa, cyclophosphamide, fludarabine and R (500 mg/ms). Rabbit anti-thymocyte globulin (ATG) was administered only in case of unrelated donors. Sixty-seven (55%) and fifty-four (45%) patients received grafts from related and unrelated donors, respectively. The crude cumulative incidence (CCI) of non-relapse mortality (NRM) was 21% at 3-years. The CCI of chronic GVHD at 3-years was 54% and 31% in recipients of matched sibling and unrelated grafts, respectively. At a median follow-up of 41 months, the estimated 3-years progression-free and overall survival were 50% and 61%, respectively. Long-term outcome was also evaluated with the composite end-point of graft-versus-host disease-free and relapse-free survival (GRFS). This is the first work evaluating the GRFS in a prospective trial of lymphomas patients: the 1 and 3-years GRFS were 40% and 34%, respectively. AlloSCT can cure a fraction of patients with rather low NRM and an encouraging PFS and GRFS.

Allogeneic Stem Cell Transplantation for Relapsed/Refractory B-Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial Including Rituximab in the Reduced Intensity Conditioning Regimen / A. Dodero, F. Patriarca, G. Milone, B. Sarina, R. Miceli, A. Iori, F. Barretta, E. Terruzzi, A. Mussetti, M. Pini, A. Bosi, A. Dominietto, N. Cascavilla, F. Onida, F. Narni, L. Farina, A. Rambaldi, P. Corradini. - In: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. - ISSN 1083-8791. - 23:7(2017), pp. 1102-1109. [10.1016/j.bbmt.2017.03.031]

Allogeneic Stem Cell Transplantation for Relapsed/Refractory B-Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial Including Rituximab in the Reduced Intensity Conditioning Regimen

F. Barretta;A. Mussetti;F. Onida;L. Farina;A. Rambaldi;P. Corradini
2017

Abstract

The treatment of patients with refractory/relapsed B-Cell non-Hodgkin lymphoma (NHL) is evolving due to the availability of novel drugs. Allogeneic stem cell transplantation (alloSCT) can be curative, but its morbidity and mortality remain a matter of concern. We conducted a multicentre prospective phase II trial to evaluate the benefit of including only one dose of Rituximab (R) in the conditioning regimen before alloSCT. The primary end-point was progression-free survival. The study enrolled 121 patients with relapsed/refractory B-cell lymphomas. The conditioning regimen consisted of thiotepa, cyclophosphamide, fludarabine and R (500 mg/ms). Rabbit anti-thymocyte globulin (ATG) was administered only in case of unrelated donors. Sixty-seven (55%) and fifty-four (45%) patients received grafts from related and unrelated donors, respectively. The crude cumulative incidence (CCI) of non-relapse mortality (NRM) was 21% at 3-years. The CCI of chronic GVHD at 3-years was 54% and 31% in recipients of matched sibling and unrelated grafts, respectively. At a median follow-up of 41 months, the estimated 3-years progression-free and overall survival were 50% and 61%, respectively. Long-term outcome was also evaluated with the composite end-point of graft-versus-host disease-free and relapse-free survival (GRFS). This is the first work evaluating the GRFS in a prospective trial of lymphomas patients: the 1 and 3-years GRFS were 40% and 34%, respectively. AlloSCT can cure a fraction of patients with rather low NRM and an encouraging PFS and GRFS.
Rituximab,lymphomas; graft-versus-host disease-free/relapse-free survival
Settore MED/15 - Malattie del Sangue
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1083879117303828-main.pdf

non disponibili

Tipologia: Publisher's version/PDF
Dimensione 677.88 kB
Formato Adobe PDF
677.88 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/491481
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact